Login to Your Account


Uni-Bio's osteoporosis candidate achieves phase III endpoint

By Shannon Ellis
Staff Writer

Wednesday, July 9, 2014

SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in postmenopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.), but since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription